Sana Biotechnology, Inc.
NASDAQ:SANABiotechnology
+$0.04 today
- Market cap
- $521.36M
- Beta
- 2.16
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.87
Volume 4.00M
Average 3.76M
Returns on capital
Sana Biotechnology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-151.8%
avg -25.0%
ROIC
-54.1%
avg -40.3%
ROA
-58.6%
avg -41.9%
Analysis
ROIC is currently the strongest return metric at -54.1% versus its period average of -40.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Steven D. Harr | President, Chief Executive Officer & Director | USD 1.15M | 56 | — | — |
Brian D. Piper | Executive Vice President & Chief Financial Officer | USD 653.04K | 54 | — | — |
Dhavalkumar D. Patel | Executive Vice President & Chief Scientific Officer | — | 65 | — | — |
Gary Meininger | Executive VP & Chief Medical Officer | — | — | — | — |
Yuko Soneoka | SVP & Head of Intellectual Property | — | — | — | — |
Aaron Grossman | Executive VP, Chief Legal Officer & Corporate Secretary | — | 54 | — | — |
John Gerecitano | Senior Vice President, Clinical Lead, Hematology & Oncology Development | — | — | — | — |
Snehal Patel | Executive VP & Chief Technical Officer | — | — | — | — |
Debra Wisdom | VP & Head of People | — | — | — | — |
Susan Wyrick | Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | — | 53 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Sana Biotechnology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SANA's management, answered from reported figures.
Who manages SANA?
Sana Biotechnology, Inc. (SANA) lists 10 active executives. The top listed executive is Dhavalkumar D. Patel, Executive Vice President & Chief Scientific Officer.
Are SANA insiders buying or selling?
Recent insider activity shows net buying of $66.08M.
Continue the stock analysis
Jump to another research area for this company.